Lam Research Corporation LRCX Receives Analyst Upgrades Amid Oversold Growth Stock Discussion Subramanian Swamy Calls for Ban on Cement Imports from Pakistan Citing Security Risks Standard Chartered Plans to Cut Over 15 of Corporate Functions Roles in Efficiency Push London Stock Exchange Group Reports Income Growth Fueled by Strong Tradeweb Performance Cheniere Reports Strong Q1 2026 Results Raises FullYear Guidance Paul Tudor Jones Says Kevin Warsh No Chance of Cutting Fed Rates Market Implications VLTO Q1 2026 Earnings EPS Beats Estimates by 435 as Operational Efficiency Shines CRDO Q1 2026 Earnings Strong EPS Beat Drives DoubleDigit Stock Surge PodcastOne Inc PODC Q1 2026 Earnings EPS Surprise Beats Estimates by 58 as Podcast Monetization Strategies Gain Traction BOBS Q1 2026 Earnings EPS Beats Estimates by Nearly 40 Despite Stock Decline BBT Q1 2026 Earnings EPS Misses Estimates Stock Edges Lower BDSX Q1 2026 Earnings EPS Surprises to the Upside Amid Operational Progress CryoCell International CCEL Edges Higher Testing Key Resistance After Support Bounce Alpha Tau Medical Warrants DRTSW Rally 689 as Key Resistance Test Looms PROCEPT BioRobotics PRCT Slips 36 as Selling Pressure Tests Key Support CanFite Biopharma CANF Slides 262 Toward 318 Support as Selling Pressure Persists AIM ImmunoTech Shares Surge Over 74 Key Levels and What to Watch Estate Planning Questions Handling CDs for a Parent in Hospice Care KPTI Q1 2026 Earnings NarrowerThanExpected Loss Boosts Investor Confidence CUBB Holds Steady Near Key Levels Amid Minimal Price Movement LRCX Q1 2026 Earnings EPS Surpasses Estimates by Nearly 5 Amid Challenging Environment TrueBlue Q1 2026 Earnings EPS Surprises with 979 Beat Amid Labor Market Uncertainty SYPR Q3 2025 Earnings Returns to Profitability with EPS of 002 as Shares Rally Vista Energy Q1 2026 Earnings EPS of 089 Reported Amid Modest Stock Decline Ingevity Corporation Q1 2026 Earnings EPS Surges 45 Above Consensus Stock Rises Franklin Resources BEN Q1 2026 Earnings Strong Earnings Beat Overshadows Revenue Uncertainty Dyne Therapeutics Q1 2026 Earnings Narrower Loss Than Expected Drives Slight Stock Uptick